|Assessment Process Complete
|For the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing primary or delayed percutaneous coronary intervention.
|Full submission received from Applicant
|NCPE assessment completed
|NCPE assessment outcome
The review group consider that prasugrel, co-administered with aspirin, is cost-effective in patients with acute coronary syndrome undergoing primary or delayed percutaneous coronary intervention in the Irish healthcare setting.